Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: Pneumococcal Vaccine

Synthetic DMARDs May Blunt Pneumococcal Vaccine Response in Systemic Sclerosis

Scott Baltic  |  January 24, 2018

NEW YORK (Reuters Health)—Pneumococcal vaccination yields a satisfactory antibody response in patients with systemic sclerosis (SSc), but synthetic disease-modifying antirheumatic drugs (DMARDs) might reduce the vaccine response in these individuals, according to a report from Sweden. The prospective study, published online Jan. 8 in Rheumatology, evaluated the response to either pneumococcal conjugate vaccine (PCV13) or…

Filed under:Conditions Tagged with:Disease-modifying antirheumatic drugs (DMARDs)pneumococcal vaccinesclerosisSystemic sclerosis

Anze Furlan / SHUTTERSTOCK.COM

How Immunosuppression May Affect COVID-19 Vaccine Response

Ruth Jessen Hickman, MD  |  June 13, 2021

Although we can expect to learn much more, preliminary data are now available on the potential safety and effectiveness of COVID-19 vaccines in rheumatology patients. The picture is likely to be nuanced, with not all types of immuno­suppressive treatments having identical impacts on vaccine response. Rheumatologists should use caution in interpreting early reports, while continuing…

Filed under:Conditions Tagged with:COVID-19immunosuppressionvaccination

The ACR Addresses Vaccine Challenges

David R. Karp, MD, PhD  |  February 18, 2021

An ACR COVID-19 Vaccine task force examined vaccine data and literature to evaluate COVID-19 vaccine safety, efficacy and interaction with medications for patients with rheumatic and musculoskeletal diseases, and to craft a living guidance document for members.

Filed under:American College of RheumatologyPresident's Perspective Tagged with:COVID-19Dr. David Karpvaccine

IBD Tied to Higher Risk of Invasive Pneumococcal Disease

David Douglas  |  September 24, 2015

NEW YORK (Reuters Health)—Patients with inflammatory bowel disease (IBD) are at slightly increased risk of invasive pneumococcal disease (IPD), according to Danish researchers. In a paper online Sept. 8 in The American Journal of Gastroenterology, Bjørn Kantsø of Statens Serum Institut in Copenhagen and colleagues note that the inappropriate immune response against infective agents seen in…

Filed under:ConditionsOther Rheumatic Conditions Tagged with:Crohn's diseaseinflammatory bowel diseaselungpneumococcal vaccine

Project Increases Pneumococcal Vaccination Rates in Rheumatology Patients

Will Boggs, MD  |  August 26, 2015

NEW YORK (Reuters Health)—A multicomponent intervention can significantly increase pneumococcal vaccination rates in pediatric rheumatology patients, researchers report. “The interventions outlined in our article can easily be implemented in pediatric rheumatology practices or other subspecialty clinics,” Dr. Julia G. Harris from Children’s Mercy Hospital, Kansas City, Mo., told Reuters Health by email. “It takes additional…

Filed under:ConditionsOther Rheumatic Conditions Tagged with:Pediatric Rheumatologypneumococcal vaccinevaccination

Vaccines and Biologics: What Rheumatologists Need to Know

Kurt Ullman  |  December 1, 2014

How vaccines, medications and rheumatic disease-related effects on immune system interact

Filed under:Biologics/DMARDsDrug UpdatesResearch Rheum Tagged with:BiologicsImmune SysteminteractionResearchRheumatic DiseaserheumatologistrheumatologyrituximabUllmanvaccines

ACR/ARHP Annual Meeting 2012: Immunosuppressed Rheumatic Disease Patients Still Candidates for Vaccines

Thomas R. Collins  |  February 1, 2013

People with rheumatic diseases can be considered to receive flu and pneumococcal vaccines even if they’re on immunosuppressive drugs

Filed under:ConditionsMeeting Reports Tagged with:DrugsImmune Systempatient carevaccine

ACR Releases New Vaccination Guideline

Ruth Jessen Hickman, MD  |  March 6, 2023

The ACR recently released its first guideline focused on vaccination in adult and pediatric patients with rheumatic and musculoskeletal diseases.1 The guideline recommends modifications to certain vaccine and medication schedules to increase immunogenicity and ensure patient safety, while encouraging providers not to miss vaccination opportunities. The Need Patients with rheumatic conditions who are on immunosuppressive…

Filed under:Clinical Criteria/GuidelinesConditionsDrug Updates Tagged with:pneumococcal vaccinerecommendationsrheumatic and musculoskeletal diseasesRMDseasonal influenza vaccinationvaccinationvaccinesvaricella zoster vaccine

A Shot of Wisdom: Vaccinations in Patients with Rheumatic Disease

Jason Liebowitz, MD, FACR  |  December 2, 2022

PHILADELPHIA—The treatment of rheumatic diseases is often a double-edged sword: immunosuppressive regimens can be very effective in reducing disease activity, but the cost of such treatments may be seen in the form of increased risk of infection. At ACR Convergence 2022, the session titled ACR Guidelines for Vaccination in Patients with Rheumatic and Musculoskeletal Diseases…

Filed under:ACR ConvergenceClinical Criteria/GuidelinesConditionsMeeting Reports Tagged with:ACR Convergence 2022COVID-19vaccination

ilusmedical / shutterstock.com

The State of Clinical Research in Vasculitis: 2021

Shubhasree Banerjee, MD, & Peter A. Merkel, MD, MPH  |  January 19, 2021

It is an exciting time in the world of vasculitis research. More clinical studies and trials are being conducted now than at any time in history. In the past ten years, four drugs have been approved by the U.S. Food & Drug Administration (FDA) and other regulatory agencies specifically for the treatment of vasculitis: Rituximab…

Filed under:ConditionsResearch RheumVasculitis Tagged with:registry

  • 1
  • 2
  • 3
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences